FDA Hypocritically Approves New Synthetic Cannabis

FDA Hypocritically Approves New Synthetic Cannabis - Weed Finder™ NewsThe U.S. Food and Drug Administration (FDA) has approved a new synthetic marijuana.  The liquid formulation of dronabinol — a synthetic form of the psychoactive compound in cannabis: tetrahydrocannabinol (THC), was officially approved a few weeks ago.

Allegedly, the synthetic cannabis will be sold under the name of Syndros and is classified Schedule III substance under the Controlled Substances Act.

Dronabinol has been sold since the mid-1980s under the name, Marinol.  The difference between Syndros and Marinol is that Syndros is a  liquid, while Marinol comes in pill form.  Therefore, Syndros might be easier to ingest.

Reports show, Insys Therapeutics, is the big pharma company currently exploiting cannabis prohibition by manufacturing both of the substandard cannabinoid replacements, Marinol and Syndros.

Marinol and Syndros are approved for treating chemotherapy induced nausea and weight loss related to AIDS. But there are some experts who are wary of synthetic cannabis, as it may have limitations. Dr. Perry Solomon, a medical marijuana physician and chief medical officer of HelloMD, told Motherboard that synthetic marijuana does not have the “entourage effect” where all the chemicals in the plant react with each other.

“I think it is really important to understand the difference between a preparation that has gone through clinical development and one that hasn’t,” said Catherine Jacobson, director of clinical research at Canadian medical cannabis company Tilray, to Motherboard. “We would like to do research on whole plant extracts. One of the holdups is the lack of safe, reliable, consistent products that are not pharmaceutical products.”

More importantly, how can the Federal Government say, “cannabis has no medicinal qualities,” while approving synthetic versions of the original for medical purposes?

(FDA Hypocritically Approves New Synthetic Cannabis – Weed Finder™ News)